Ravi Biolife is an API manufacturer based in India. It holds 3 active US drug master files and 4 valid CEPs across a filed portfolio of 5 molecules. Its filings concentrate with EEC_EAEU and MINSA (CR). Customs aggregates show $180K of exports covering 32 molecules to 9 destinations in 2025.
| Site | FDA FEI |
|---|---|
| Mumbai, India | Not on file |
| Raigad, India | 3027545288 |
| Mumbai, India | Not on file |
| Molecule | Regulators | Docs |
|---|---|---|
| Gemcitabine | EDQM, US FDA | 2 |
| Methotrexate | EDQM, US FDA | 2 |
| Nilotinib | EDQM | 1 |
| Pemetrexed | US FDA | 1 |
| Pemetrexed Disodium | EDQM | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| EEC_EAEU | 3 | None |
| MINSA (CR) | 1 | None |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $47K | 3 |
| 2025 | Not reported | $180K | 9 |
| 2024 | Not reported | $58K | 4 |
| 2023 | Not reported | $2K | 1 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Ask Fred what the record holds on Ravi Biolife, including filings and inspection history.
Chat with Fred, your AI analystRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.